（原标题：三元基因涨20.76%，龙虎榜上机构买入927.48万元，卖出419.77万元） 三元基因（837344）今日上涨20.76%，全天换手率12.67%，成交额4.83亿元，振幅29.58%。龙虎榜数据显示，机构净买入507.71万元，营业部席 位合计净卖出2285.62万元。 北交所公开信息显示，当日该股因日涨跌幅达到20.76%上榜，机构专用席位净买入507.71万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交1.19亿元，其中，买入成交额为5051.45万元，卖出成交额为6829.36万元，合计净 卖出1777.91万元。 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国金证券股份有限公司深圳分公司 | 1112.04 | 576.56 | | 买二 | 机构专用 | 927.48 | 419.77 | | 买三 | 国联民生证券股份有限公司国联民生证券北京分公司 | 883.80 | 0.00 | | 买四 | 国信证券股份有限公司深圳红岭中路证券营业部 | 812.80 | 6 ...

三元基因公告，公司近日收到国家药品监督管理局核准签发的重组人干扰素α1b喷雾剂(25万IU(25μg)： 5ml/支)《药品补充申请批准通知书》。此次批准通知修订了说明书中的【注意事项】项，将"3.本品仅 供外用，切勿入口，避免接触眼睛。"修订为"3.本品仅供外用，严格遵照医嘱使用，避免接触眼 睛。"该药品于2011年首次批准上市，用于治疗由病毒引起的初发或复发性面部单纯疱疹，具有抗病毒 和免疫调节双重作用。2024年，该产品成功中选江西省医保局发布的《干扰素省际联盟集中带量采购中 选结果通知》，约定采购期4年。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 837344 | 三元基因 | 34.84 | 20.76% | 14.39万 | | 4.83亿 | | 430047 | 诺思兰德 | 25.25 | 11.14% | 14.89万 | | 3.62亿 | | 301080 | 百普赛斯 | 56.66 | 8.07% | 5.96万 | | 3.28亿 | | 603590 | 康辰药业 | 60.15 | 7.93% | 14.36万 | | 8.41亿 | | 300122 | 智飞生物 | 25.06 | 6.50% | 129.92万 | | 31.54亿 | | 688136 | 科兴制药 | 50.47 | 6.41% | 11.16万 | | 5.51亿 | | 688293 | 奥浦迈 | 58.96 | 4.59% | 2.95万 | | 1.73亿 | | 300485 | 赛升药业 | 15.55 | 4.43% | 52.62万 | | 8.08亿 | ...

Group 1: Market Performance - The average daily change for the North Exchange (北证) and A-shares (A股) shows significant fluctuations, with a peak of 30% for Tianrun Technology (天润科技) on July 25, 2025[8] - The trading volume for the North Exchange reached a total of 600 billion CNY, with an average turnover rate of 16% as of July 25, 2025[6] - The average price-to-earnings ratio (PE) for companies listed on the North Exchange varies significantly across industries, with some sectors showing a PE as high as 516.07[12] Group 2: Stock Performance - The top-performing stocks on July 25, 2025, include Tianrun Technology with a 30% increase and a market capitalization of 29.19 billion CNY[8] - Conversely, the worst-performing stock, Jikang Technology (基康技术), saw a decline of 12.56% with a market capitalization of 52.76 billion CNY[9] - The average daily change for the North Exchange was notably higher than that of the A-share market, indicating a more volatile trading environment[7] Group 3: Risks and Challenges - The report highlights risks including lower-than-expected policy support, insufficient technological innovation, and increased market competition[13] - Market volatility remains a significant concern, impacting investor sentiment and stock performance across various sectors[13]

Group 1: Stock Performance - Yiming Pharmaceutical achieved a 10.00% increase over two consecutive days, driven by developments in Tibet and medical technology [3] - Kantai Medical saw a first board listing with a 20.03% rise, attributed to medical device advancements [4] - Zhengchuan Co. also debuted on the first board with a 9.99% increase, linked to medicinal glass [3] - Yuheng Pharmaceutical and Tianmu Pharmaceutical both recorded first board listings with increases of 10.09% and 10.00% respectively, related to the pharmaceutical sector [3] Group 2: AI and Robotics - Zhi Zhen Technology and Zhongdian Xinlong both debuted on the first board with a 10.01% increase, associated with computing power and machine learning [6] - Hubei Broadcasting and Duolun Technology also saw first board listings with increases of 10.04% and 9.95%, driven by computing power and AI applications [7] - The M-Robots open-source project was announced, aiming to create a unified robot operating system [11] Group 3: Infrastructure and Energy - The announcement of a 1.2 trillion yuan investment in a super hydropower project has led to significant interest in related stocks [13][16] - Nanfang Road Machinery and Tuoshan Heavy Industry both achieved consecutive board listings with increases of 9.99% and 10.01%, linked to engineering machinery [15] Group 4: Tourism and Hospitality - The demand for various types of tourism, including educational and family trips, has surged, with national railways reporting 341 million passenger trips [18][19] - Sizhizang Tourism and Tianfu Cultural Tourism both recorded first board listings with increases of 9.99% and 10.04%, reflecting the growing tourism sector [20] Group 5: Market Trends - The stock market has shown a strong focus on sectors such as robotics, AI, and infrastructure, with multiple companies achieving significant stock price increases [22][23]

Group 1 - The core viewpoint of the articles highlights the increasing activity in the innovative drug sector, driven by favorable government policies and the introduction of a commercial health insurance directory for innovative drugs [1][2] - Since 2025, the government has proposed multiple policies to optimize drug procurement and support innovative drugs, indicating a positive policy environment for the pharmaceutical industry [1] - The 11th batch of national drug procurement is underway, with expectations for optimized rules and price reductions, moving away from a focus on minimum pricing to a more quality-controlled approach [1] Group 2 - Ever since the 14th Five-Year Plan, a total of 402 new drugs have been included in the medical insurance directory, with innovative drug spending projected to reach 3.9 times that of 2020 by 2024, reflecting a 40% annual growth rate [2] - The establishment of a commercial health insurance directory for innovative drugs will provide a supplementary payment channel for drugs not included in the national medical insurance directory, with over 100 drugs already submitted for approval [2] - The precise adjustment of medical insurance policies is reshaping the pharmaceutical industry ecosystem, transitioning from price wars to value wars, and clearing out low-quality production capacity to create market space for high-quality enterprises [2]

Group 1 - The A-share biopharmaceutical sector experienced a significant afternoon rally, with notable increases in stock prices [1] - Zhifei Biological surged over 14%, while Watson Bio rose more than 12% [1] - Other companies such as Kangtai Biological, Sanyuan Gene, Bohui Innovation, Baike Biological, and Zhixiang Jintai also saw gains [1]

证券代码：837344 证券简称：三元基因 公告编号：2025-051 北京三元基因药业股份有限公司 公司聘任熊纷女士为证券事务代表，任职期限至第四届董事会任期届满 之日止，自 2025 年 7 月 8 日起生效。该人员持有公司股份 0 股，占公司股 本的 0.00%，不是失信联合惩戒对象。 证券事务代表任命公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、证券事务代表任命的基本情况 北京三元基因药业股份有限公司（以下简称"公司"）于 2025 年 7 月 8 日召开第四届董事会第六次会议，审议通过了《关于聘任公司证券事务 代表的议案》。 （上述人员简历详见附件） 二、合规性说明及影响 （一）人员变动的合规性说明 三、备查文件 （一）与会董事签字确认并加盖董事会印章的公司《第四届董事会第 六次会议决议》。 北京三元基因药业股份有限公司 董事会 2025 年 7 月 9 日 附件: 熊纷女士简历 熊纷女士，1995 年出生，中国国籍，无境外永久居留权，大学本科学 历，取得中级会计职称，持有中国上市公 ...

证券代码：837344 证券简称：三元基因 公告编号：2025-050 北京三元基因药业股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 7 月 8 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 6.会议列席人员：监事会成员、董事会秘书以及公司其他高级管 理人员列席了会议。 7.召开情况合法、合规、合章程性说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事程十庆因公务出差缺席，委托董事程永庆代为表决。 董事杨大军、范保群、钱爱民、邵荣光、胡左浩因工作原因以通 讯方式参与表决。 二、议案审议情况 （一）审议通过《关于聘任公司证券事务代表的议案》 4.发出董事会会议通知的时间和方式：2025 年 6 月 26 日以通讯 方式发出。 5.会议主持人：会议由程永庆董事长主持。 该议案不 ...

本公司及董事会全体成员及相关股东保证公告内容不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 一、 减持主体减持前基本情况 证券代码：837344 证券简称：三元基因 公告编号：2025-049 北京三元基因药业股份有限公司 股东减持股份结果公告 三、 备查文件 （一）《浙江圣达科技发展有限公司减持结果告知函》。 | 股东名称 | 股东身份 | 持股数量 | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | | | | （股） | （%） | | | 浙江圣达科技 | 持股 5%以上股东 | 14,570,255 | 11.9615% | 进入北交所前取得 | | 发展有限公司 | | | | | 二、 减持计划的实施结果 （一） 股东因以下原因披露减持计划实施结果： | | | 减持数 | | | | | 减持 | | 当前持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 减持数量 | 量占总 | 减持 | 减持 | 减持 ...